In the Media
Australian biotech back on the international stage
Jun 7th, 2022
Starpharma's CEO Dr Jackie Fairley was interviewed by ausbiz during Starpharma's visit to the United States for the American Society of Clinical Oncology (ASCO) Annual Meeting as well as partnering discussions.
Read MoreStarpharma one of a number of Australian companies in the US for major oncology conference
Jun 7th, 2022
"For the first time in more than two years, a number of Australian biotechnology companies are in the US for one of the world's most important oncology events - the global conference of the American Society of Clinical Oncology (ASCO)." Starpharma featured in Biotech Dispatch during its visit to the United States for ASCO.
Read MoreStarpharma's nasal spray effective against influenza A & B virus
May 23rd, 2022
BioSpectrum Asia features Viraleze, following Starpharma's announcement about SPL7013's virucidal activity in influenza A and B.
Read MoreStarpharma’s (ASX:SPL) antiviral agent fights back against against influenza virus
May 18th, 2022
The Market Herald reports on Starpharma’s SPL7013 agent, which achieved up to 99.7 per cent reduction in viral activity against two types of influenzas virus.
Read MoreStarpharma (ASX:SPL) to relaunch VIRALEZE treatment in UK
Apr 1st, 2022
The Market Herald features Starpharma following its latest announcement related to the relaunch of VIRALEZE™ in the UK.
Read MoreActive agent in Australian-developed nasal spray highly active against 'Omicron'
Mar 2nd, 2022
Australian biotechnology and life sciences media platform, BiotechDispatch, featured the news of Starpharma's latest announcement regarding SPL7013's virucidal activity against Omicron.
Read MoreStarpharma’s (ASX:SPL) nasal spray outperforms competitors against Omicron variant
Mar 1st, 2022
"Starpharma’s (SPL) antiviral nasal spray has achieved a greater than 99.5 per cent reduction of virus infectivity against the Omicron variant of SARS-CoV-2." The Market Herald reports on Starpharma, following the company's latest announcement.
Read MoreStarpharma (ASX:SPL) pens distribution deal in Saudi Arabia
Feb 3rd, 2022
The Market Herald reports on Starpharma's new partnership with Etqan & Nazahah for the sales and distribution of VIRALEZE™ in Saudi Arabia.
Read MoreStarpharma’s (ASX:SPL) December quarter boosted by VIRALEZE success
Jan 28th, 2022
The Market Herald reports on Starpharma, following the release of the company's Quarterly Cashflow and Activities Report.
Read MoreAustralian homegrown COVID-19 pipeline shows signs of maturity
Jan 27th, 2022
Starpharma's CEO Dr Jackie Fairley was interviewed by BioWorld about the company's antiviral nasal spray VIRALEZE™.
Read MoreStarpharma announces early orders following Vietnam distribution agreement
Dec 14th, 2021
BiotechDispatch report on Starpharma's latest announcement related to the launch of VIRALEZE™ in Vietnam.
Read MoreStarpharma (ASX:SPL) tables $2m in Vietnam VIRALEZE orders
Dec 13th, 2021
"Since October, pharmaceutical company Starpharma (SPL) has received VIRALEZE orders totaling more than $2 million for Vietnam", as reported in The Market Herald.
Read MoreNovel Cabazitaxel Formulation Shows Promise for Metastatic Prostate Cancer
Nov 30th, 2021
Targeted Oncology features Starpharma's latest DEP® announcement - the release of positive interim results from the prostate cancer cohort of Starpharma's ongoing phase 2 trial of DEP® cabazitaxel.
Read MoreStarpharma reports positive interim results from Phase 2 DEP cabazitaxel study in prostate cancer
Nov 27th, 2021
Starpharma's positive interim results from its ongoing phase 2 trial of DEP cabazitaxel featured in Seeking Alpha.
Read MoreStarpharma Releases Positive DEP® Phase 2 Interim Results In Prostate Cancer
Nov 27th, 2021
British Herald reports on Starpharma's announcement, regarding the positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel.
Read MoreStarpharma Announces Encouraging Interim Results for Prostate Cancer Drug
Nov 27th, 2021
Gene Online reports on the news of Starpharma's latest announcement - the release of positive interim results from the prostate cancer cohort of Starpharma's ongoing phase 2 trial of DEP® cabazitaxel.
Read MoreStarpharma (ASX:SPL) continues VIRALEZE success in December quarter
Oct 29th, 2021
"Starpharma (SPL) has released its September quarterly report, with the quarter again highlighted by the continued success of VIRALEZE," as reported by The Market Herald.
Read MoreStarpharma signs distribution agreement for antiviral in Vietnam
Oct 26th, 2021
News of Starpharma signing an initial supply contract for VIRALEZE™ in Vietnam featured in BiotechDispatch. Read the article here.
Read MoreStarpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam
Oct 26th, 2021
The Market Herald features news of Starpharma's latest supply arrangement for VIRALEZE™ in Vietnam.
Read MoreNanotechnology Offers New Ways To Fight An Endless Pandemic
Oct 18th, 2021
Starpharma's VIRALEZE™ antiviral nasal spray was featured in Report Wire.
Read More